Insider buying surged in February. Warren Buffett continues to build a stake in a media stock, and IPOs tempted some insiders ...

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

Every investor in 89bio, Inc. (NASDAQ:ETNB) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 58% ownership. That is, ...

SG Americas Securities LLC lifted its holdings in 89bio, Inc. (NASDAQ:ETNB – Free Report) by 18.3% during the fourth quarter, ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of 89bio (NasdaqGM:ETNB) with a Outperform ...

Ra Capital Management, a director and more than 10% owner of 89bio Inc. (ETNB), bought common stock worth $49.99 million last ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

Inc. (NASDAQ:ETNB – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven analysts that ...